Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)
Commercial Sponsor
Incyte Corporation
Summary
Eligible patients will be randomised into Group A or Group B. Depending on their allocation, patients will receive carboplatin on Day 1, paclitaxel on Days 1,8 and 15, and either a placebo or the experimental treatment, retifanlimab, on Day 1 of each 28 day cycle.